Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders
22 juin 2021 08h30 HE | Neurona Therapeutics
Syndicate includes premier healthcare investors steeped in neurology Erica Whittaker, Ph.D., head of UCB Ventures, joins Neurona’s board of directors Latest financing brings total...
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)
16 juin 2021 08h00 HE | Neurona Therapeutics
Supporting data in preclinical model of drug-resistant epilepsy demonstrate seizure-freedom in 70% of the NRTX-1001 cell therapy treatment group versus 5% in the control group Data demonstrate...
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy
19 avr. 2021 08h00 HE | Neurona Therapeutics
SAN FRANCISCO, April 19, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing neural cell therapies for the treatment of neurological disorders, today announced the...